Nippon Kayaku Co., Ltd.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1916-06-05
- Employees
- 5.9K
- Market Cap
- -
Clinical Trials
32
Active:0
Completed:10
Trial Phases
5 Phases
Phase 1:10
Phase 2:9
Phase 3:2
+2 more phases
Drug Approvals
2
NMPA:2
Drug Approvals
Bleomycin Hydrochloride for Injection
- Product Name
- BLEOCIN
- Approval Number
- 国药准字HJ20171103
- Approval Date
- Jan 30, 2022
NMPA
Clinical Trials
Distribution across different clinical trial phases (31 trials with phase data)• Click on a phase to view related trials
Phase 1
10 (32.3%)Phase 2
9 (29.0%)Not Applicable
5 (16.1%)phase_1_2
4 (12.9%)Phase 3
2 (6.5%)Phase 4
1 (3.2%)A Phase III Study of NK105 in Patients With Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer Nos Metastatic Recurrent
- Interventions
- First Posted Date
- 2012-07-19
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 436
- Registration Number
- NCT01644890
- Locations
- 🇯🇵
Japan Sites, Tokyo, Etc., Japan
Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
Phase 2
Terminated
- Conditions
- Bladder Cancer
- Interventions
- Drug: EO9 (Apaziquone)Drug: Placebo
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT01475266
- Locations
- 🇯🇵
Nippon Kayaku Investigational site 103, Yokosuka, Kanagawa, Japan
🇯🇵Nippon Kayaku Investigational site 107, Kashihara, Nara, Japan
🇯🇵Nippon Kayaku Investigational site 109, Kurashiki, Okayama, Japan
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
Phase 1
Completed
- Conditions
- Advanced Solid TumorsMetastatic Colorectal Cancer
- Interventions
- Drug: NK012 and 5-FU
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT01238939
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
Phase 1
Completed
- Conditions
- Advanced Solid TumorsMetastatic Triple Negative Breast Cancer
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT01238952
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection
- First Posted Date
- 2010-01-20
- Last Posted Date
- 2014-01-08
- Lead Sponsor
- Nippon Kayaku Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT01052259
- Locations
- 🇯🇵
Sapporo City General Hospital, Sapporo, Hokkaido, Japan
🇯🇵Osaka University Graduate School of Medicine, Suita, Osaka, Japan
🇯🇵Toda Central General Hospital, Toda, Saitama, Japan
- Prev
- 1
- 2
- 3
- Next
News
No news found